|
|||||
|
|
||||||
JCO Early Release, published online ahead of print Oct 26 2009
Received August 13, 2008 In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
From the AVENIR L'Institut National de la Santé et de la Recherche Médicale (INSERM) Integrative Cancer Immunology Team, INSERM U872; Université Paris-Descartes; Cordeliers Research Center; Université Pierre et Marie Curie Paris 6; Departments of Immunology, Pathology, and General and Digestive Surgery of the Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Paris; Departments of General and Digestive Surgery, and Pathology, Avicenne Hospital, Bobigny, France; Institute for Genomics and Bioinformatics, Graz University of Technology; and Institute of Pathology, Medical University of Graz, Graz, Austria. * To whom correspondence should be addressed. E-mail: jerome.galon{at}crc.jussieu.fr
Purpose: Many patients who present with early-stage colorectal cancer (International Union Against Cancer TNM stages I and II) are nevertheless at high risk of relapse. We hypothesized that intratumoral immune reaction could influence their prognosis. Patients and Methods: The intratumoral immune reaction was investigated in 29 tumors by large-scale real-time polymerase chain reaction. Cytotoxic (CD8) and memory (CD45RO) T cells were quantified by immunohistochemical analyses of tissue microarrays from the center (CT) and the invasive margin (IM) of the 602 tumors from two independent cohorts. The results were correlated with tumor recurrence and patient survival. Results: Patients with a strong infiltration of CD45RO+ cells in the tumor exhibited an increased expression of T-helper 1 and cytotoxicity-related genes. Densities of CD45RO+ and CD8+ cells in tumor regions (CT/IM) classified the patients into four distinct prognostic groups based on the presence of high density of each marker in each tumor region. The four groups were associated with dramatic differences in disease-free, disease-specific, and overall survival (all P < .0001). Five years after diagnosis, only 4.8% (95% CI, 0.6% to 8.8%) of patients with high densities of CD8+ plus CD45RO+ cells had tumor recurrence, and 86.2% (CI, 79.4% to 93.6%) survived. In contrast, the tumor recurred in 75% (95% CI, 17% to 92.5%) of patients with low densities of these cells, and only 27.5% (95% CI, 10.5% to 72%) survived (all P < .0001). Multivariate analyses showed that the immune criteria had independent effects on the rates of complete remission and survival. Conclusion: The combined analysis of CD8+ plus CD45RO+ cells in specific tumor regions could provide a useful criterion for the prediction of tumor recurrence and survival in patients with early-stage colorectal cancer.
|
|
|||||||||||
|
Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|